Table 1.
Baseline clinicopathologic characteristics
| Variables | Training set | Test set |
|---|---|---|
| Gender | ||
| Male | 56 (73,6%) | 63 (74,1%) |
| Female | 20 (26,3%) | 22 (25,8%) |
| Age | ||
| Median (Q1-Q3) | 62,0 (58,3–67,0) | 65,0 (57,0–70,0) |
| BMI | ||
| Median (Q1-Q3) | 24,0 (20,3–27,3) | 24,0 (22,0–27,8) |
| Smoker | ||
| No | 3 (3,9%) | 2 (2,3%) |
| Wean | 47 (61,8%) | 33 (38,8%) |
| Active | 26 (34,2%) | 26 (30,5%) |
| Missing | 0 (0%) | 24 (28,2%) |
| Performans status (PS) | ||
| 0 | 42 (55%) | 35 (41,2%) |
| 1 | 30 (39,4%) | 46 (54,1%) |
| 2 | 4 (5,2%) | 4 (4,7%) |
| Radiation dose | ||
| 60 Gy | 30 (39,5%) | 5 (5,8%) |
| 66 Gy | 46 (60,5%) | 59 (68,6%) |
| 70 Gy | 0 (0%) | 21 (24,4%) |
| Of which SBRT on primary tumor¹ | 8 (10,5%) | 0 (0%) |
| Chemotherapy | ||
| Paclitaxel | 18 (23,6%) | 29 (34,1%) |
| Pemetrexed | 20 (26,3%) | 9 (10,5%) |
| Vinorelbine | 36 (47,3%) | 47 (55,2%) |
| Gemcitabine | 2 (2,6%) | 0 (0%) |
| Sequential | 2 (2,6%) | 0 (0%) |
| Concomitant | 71 (93,4%) | 66 (77,6%) |
| Missing | 3 (3,9%) | 19 (22,3%) |
| Time between last radiotherapy session and first DURVALUMAB treatment | ||
| Mean (days) | 29 (3–67) | 35 (3–88) |
| Stage | ||
| < 3 | 2 (2,6%) | 0 (0%) |
| 3 A | 28 (36,7%) | 22 (25,8%) |
| 3B | 39 (51,3%) | 48 (56,4%) |
| 3 C | 7 (9,2%) | 15 (17,6%) |
| Histology | ||
| Adenocarcinoma | 42 (55,2%) | 38 (44,7%) |
| Squamous cell carcinoma | 26 (34,2%) | 36 (42,3%) |
| Sarcomatoid | 2 (2,6%) | 1 (1,2%) |
| Undifferenciated | 6 (7,9%) | 10 (11,7%) |
| PDL1 | ||
| < 1% | 13 (17,1%) | 16 (18,8%) |
| 1–49% | 28 (36,7%) | 39 (45,8%) |
| >=50% | 31 (40,7%) | 27 (31,7%) |
| Missing | 4 (5,2%) | 3 (3,5%) |
| ALK/ROS1 mutation (adenocarcinoma only) | ||
| ALK | 1 (1,3%) | 1 (1,2%) |
| ROS1 | 1 (1,3%) | 1 (1,2%) |
| Oncogenic addiction (adenocarcinoma only) | ||
| No mutation | 16 (38,1%) | 18 (47,3%) |
| Mutation | 26 (61,9%) | 18 (47,3%) |
| Missing | 0 (0%) | 2 (5,3%) |
| Of which EGFR mutation | 2 (4,8%) | 3 (7,9%) |
| Neutrophil count (G/L) on assessment biology before first Durvalumab infusion | ||
| Median (Q1-Q3) | 3,05 (2,17 − 4,20) | 3,42 (2,44 − 4,66) |
| Lymphocytes count (G/L) on assessment biology before first Durvalumab infusion | ||
| Median (Q1-Q3) | 0,850 (0,613-1,10) | 0,885 (0,590-1,09) |
| NLR on assessment biology before first Durvalumab infusion | ||
| Median (Q1-Q3) | 3,87 (2,36 − 5,61) | 4,10 (2,76 − 5,41) |
¹stereotactic body radiation therapy